Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAMS-Anxious distress: Aripiprazole augmentation in major depressive disorder with anxious distress
KCT0009950Phase 4Not yet recruiting
- Sponsor
- Korea Otsuka Pharmaceutical
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole in major depressive disorder (MDD), sponsored by Korea Otsuka Pharmaceutical. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on KCT0009950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009950.